Chemspace

2024 brought its share of challenges, but thanks to your support and trust, it was also a year of growth, learning, and teamwork. 🔥   Looking ahead to 2025, we are filled with hope and determination. We believe the coming year will bring new successes, peace, and happiness for all of us. Thank you for being part of our journey. Your support means the world to us, and we can’t wait to continue building great things together. Wishing you joy, inspiration, and prosperity this holiday season and beyond. Let's make the new year even more impressive with remarkable discoveries and achievements together.   See you in 2025! The Chemspace Team 💚

Today, the transient receptor potential cation channel subfamily V member 1 (TRPV1) is considered a promising target for developing new analgesics with improved efficacy and safety profiles. To facilitate the study of its function and role in cascades of events leading to pain signal transmission and other biological processes, we have curated a set of Chemspace Biologics (https://lnkd.in/e9-UE8qG). TRPV1 is a non-selective cation channel and polymodal receptor and is activated by harmful stimuli such as noxious temperatures, capsaicin (the active ingredient in chili peppers), and acidic environments. TRPV1 demonstrates multifaceted pathophysiological significance, mediating critical mechanisms in nociception, neuroinflammation, oncogenesis, and metabolic homeostasis. Chemspace offers specially selected Biologics (antibodies, peptides, proteins, RNAs, etc.) to support the study of TRPV1's role in pathological and physiological conditions. If you are interested in exploring TRPV1 or other innovative perspective targets, or if you would like to utilize our biological services, please reach out to us at info@chem-space.com. We will be glad to support your scientific journey.

In November 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc), the first-in-class menin inhibitor, for the treatment of relapsed/refractory acute leukemia with KMT2A translocation in patients aged 1 year and older. Analyzing the structure of revumenib, a 2,7-diazaspiro[3.5]nonane fragment caught our attention. This unique moiety has inspired us to offer a set of building blocks for your drug discovery projects - https://lnkd.in/eF8cfsjd. Even in an early-phase clinical trial, revumenib showed promising efficacy, inducing complete remission in about one-third of participants with acute myeloid leukemia. This drug prevents the interaction between menin and the rearranged KMT2A protein, commonly associated with aggressive forms of blood cancer. By targeting this pathway, revumenib effectively halts the growth of leukemic cells, providing a targeted therapeutic option for this challenging disease. If you want to acquire building blocks or learn more about our offerings, please get in touch with us at sales@chem-space.com. 📧 #chemspace #FDA #research #inhibitor #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #chemicalindustry #science

Chemspace is excited to bring you an exclusive 55% discount on selected compounds from ChemScene - available until December 25th, 2024! Discounted prices are accessible exclusively after signing in. Do not miss this opportunity to save big with ChemScene’s special holiday offer. For more details, reach out to us at sales@chem-space.com. #chemspace #sale #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry

This year has been a remarkable journey for our Drug Discovery Team! We have faced exciting challenges head-on and achieved some truly outstanding milestones:     ✅ Overall, 41 projects were successfully completed in 2024!   ✅ 7 V-SYNTHES (https://lnkd.in/eFUHXe2p) projects, including one that ranked our team among the top five performers in the CACHE Challenge #2.  ✅ 10 projects utilizing our unique service that combines DNA-encoded libraries and machine learning (DEL-ML). https://lnkd.in/eWWZ73QQ  ✅ 12 molecular docking projects.   ✅ 12 integrated projects, bringing together the best of our expertise. https://lnkd.in/e3phjAzJ   2024 pushed us to new heights, and we are proud to say we delivered 100%!      Looking forward to even greater achievements and partnerships in 2025!🚀     Stay with Chemspace 💚 #chemspace #2024 #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #chemicalindustry #science

Last week, Enamine Ltd. and Elsevier announced an exciting collaboration! Enamine’s 43 million make-on-demand (MADE) analog compounds will now be integrated into Reaxys, providing researchers with an unparalleled resource for chemical discovery.     We are proud to support this collaboration, bringing our expertise in generating and exploring ultra-large chemical datasets. Chemspace will provide its infrastructure to streamline order processing.     Chemspace is your expert provider of integrated services! 💚 We deliver end-to-end services covering every facet of the Drug Discovery process up to pre-clinical studies. We will navigate you through accessible chemical space, help to find the right molecules, and assist with sourcing, delivery, and testing these molecules.  #chemspace #openscience #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #chemicalindustry #science

2024 was packed with amazing moments as Chemspace hit the road, attending 15 conferences worldwide. From connecting with amazing people to sharing our expertise and learning from others, it has been a year full of growth and collaboration.    We have captured some of these moments in a video - check it out to see the highlights from the conferences we attended this year! 🔥   Thank you to everyone who visited our booth, joined our talks, or simply stopped by to say hello. We are already looking forward to seeing you again in 2025! 💚 #chemspace #conference #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #chemicalindustry #2024

Did you miss any of our November news and highlights? Here is a comprehensive summary of our posts for this month: https://lnkd.in/grFWd_wa News&cllaborations:  1) Enamine REAL Space update! Now offering easy access to 75 billion molecules at https://lnkd.in/gBSX59N5  2) 10% off on the REAL and Freedom compounds until December 31.  3) New video about Integrated Drug Discovery with Chemspace. #Meet_Chemspace_Team:  1) Let’s introduce our Sourcing Manager – Anna Borovska! Building Blocks and Screening Compound Sets:  1) “Molecule Builder”- a New Post About Aprocitentan.  2) Analogs to New Biological Tools Compounds – discover analogs set to dual LSD-HDAC inhibitor. Biologics for Research  1) Discover Interleukin-17 (IL-17) focused Biologics with Chemspace. #chemspace #openscience #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #chemicalindustry #science

Combinatorial libraries have revolutionized the way we explore chemical space, offering access to an immense range of compounds. Chemspace Freedom Space 3.0 is a unique collection of 5 billion molecules that was created using ML-based filters. However, managing and searching such vast enumerated databases can often be resource-intensive and complex. But now, we have a perfect solution for you! 💯 Freedom Space 3.0 is now available for synthon-based search via the RDKit library (https://buff.ly/3OAL61M). With access to it, you can perform exact match, substructure searches, and similarity searches via fingerprints efficiently. All you need are the full synthon and reaction files, and we have them ready for you. Just email us at sales@chem-space.com. More details about space generation and data access to the enumerated version here: https://buff.ly/4ghfeLz RDKit blog article: https://buff.ly/3VoeOv0

PharmacoNet is a great new implementation of classical pharmacophore modeling, enhanced by deep learning approaches, developed by Seonghwan Seo and Woo Youn Kim. The authors clearly describe the approach's architecture and honestly disclose the results of comparing it with already-known methods. I highly recommend it for reading. Blog post: https://lnkd.in/d97jb-zN Original paper: https://lnkd.in/dVMpp3b3 GitHub: https://lnkd.in/dpUbHNwE